Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7272   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-001629-41
    Sponsor's Protocol Code Number:DSC/15/2357/53
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-15
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2017-001629-41
    A.3Full title of the trial
    A randomised, double-blind, placebo-controlled study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscular Dystrophy
    Studio randomizzato, in doppio cieco, controllato verso placebo per valutare gli effetti micro- e macroscopici sui muscoli, la sicurezza e la tollerabilit¿ e l¿efficacia di givinostat in pazienti affetti da distrofia muscolare di Becker.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscular Dystrophy.
    Studio per valutare gli effetti micro- e macroscopici sui muscoli, la sicurezza e la tollerabilità e l'efficacia di givinostat in pazienti affetti da distrofia muscolare di Becker.
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberDSC/15/2357/53
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorITALFARMACO S.P.A.
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportITALFARMACO S.p.A.
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationITALFARMACO S.p.A.
    B.5.2Functional name of contact pointClinical Research and Development
    B.5.3 Address:
    B.5.3.1Street AddressVia dei Lavoratori, 54
    B.5.3.2Town/ cityCinisello Balsamo (MI)
    B.5.3.3Post code20092
    B.5.3.4CountryItaly
    B.5.4Telephone number+390264431
    B.5.5Fax number+390264433554
    B.5.6E-mailp.bettica@italfarmaco.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/12/1009
    D.3 Description of the IMP
    D.3.1Product nameGivinostat (hydrochloride monohydrate)
    D.3.2Product code ITF2357
    D.3.4Pharmaceutical form Oral suspension
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGivinostat (hydrochloride monohydrate)
    D.3.9.1CAS number 732302-99-7
    D.3.9.2Current sponsor codeITF2357
    D.3.9.3Other descriptive nameGIVINOSTAT
    D.3.9.4EV Substance CodeSUB30834
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOral suspension
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Becker Muscular Dystrophy (BMD)
    Distrofia Muscolare di Becker (DMB)
    E.1.1.1Medical condition in easily understood language
    Genetic disease characterized by degeneration of muscle fibers
    Malattia genetica caratterizzata da una degenerazione delle fibre muscolari
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10059117
    E.1.2Term Becker's muscular dystrophy
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To establish the histological effects of givinostat versus placebo administered over 12 months.
    Stabilire gli effetti istologici di givinostat rispetto a placebo somministrato per 12 mesi.
    E.2.2Secondary objectives of the trial
    1. To establish the macroscopic muscle effects of givinostat versus placebo administered chronically over 12 months assessed by MRI/MRS.
    2. To establish the other histological effects of givinostat versus placebo administered over 12 months.
    3. To establish the efficacy of givinostat versus placebo administered chronically over 12 months in slowing disease progression.
    4. To assess the safety and tolerability of givinostat versus placebo administered chronically.
    5. To evaluate the pharmacokinetic (PK) profile of givinostat administered chronically in the target population.
    6. To evaluate the impact of givinostat versus placebo administered chronically on quality of life and activities of daily living.
    1. Stabilire gli effetti macroscopici a livello muscolare di givinostat rispetto a placebo somministrato come terapia cronica per 12 mesi valutati tramite risonanza magnetica (Magnetic Resonance Imaging - MRI) / spettroscopia di risonanza magnetica (Magnetic Resonance Spectroscopy - MRS).
    2. Stabilire gli altri effetti istologici di givinostat rispetto a placebo somministrati per 12 mesi.
    3. Stabilire l'efficacia di givinostat rispetto a placebo somministrato come terapia cronica per 12 mesi nel rallentare la progressione di malattia.
    4. Valutare la sicurezza e tollerabilità di givinostat rispetto a placebo somministrato come terapia cronica.
    5. Valutare il profilo farmacocinetico (PK) di givinostat somministrato come terapia cronica nella popolazione target.
    6. Valutare l'impatto di givinostat rispetto a placebo somministrato come terapia cronica sulla qualità della vita e le attivit¿ della vita quotidiana.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Ambulant male patients aged =18 years to =65 years at randomization with BMD diagnosis confirmed by genetic testing.
    2. Able and willing to give informed consent in writing.
    3. Able to perform 6MWT at screening with a minimum distance of 200 m and maximum distance of 450 m.
    4. If in treatment with systemic corticosteroids and/or ACE inhibitor, and/or ß or a adrenergic receptor blocker, no significant change in dosage or dosing regimen (excluding changes related to body weight change) for a minimum of 6 months immediately prior to start of study treatment.
    5. Patients must be willing to use adequate contraception. Contraceptive methods must be used from Randomization through 3 months after the last dose of study treatment.
    1. Pazienti di sesso maschile in grado di deambulare di età compresa tra =18 e = 65 anni alla randomizzazione con diagnosi di BMD confermata da test genetico.
    2. Pazienti in grado e disposti a dare il proprio consenso informato per iscritto.
    3. Pazienti in grado di effettuare il test del cammino in 6 minuti (6MWT) con una distanza minima di 200 m e una distanza massima di 450 m.
    4. Se in trattamento con corticosteroidi sistemici e/o ACE inibitore, e/o ß bloccante o agenti bloccanti a adrenergici, non devono esserci modifiche significative nel dosaggio o nel regime di dosaggio (ad esclusione delle modifiche relative alla variazione di peso corporeo) per almeno 6 mesi immediatamente precedenti all'inizio del trattamento in studio.
    5. Pazienti disponibili ad utilizzare adeguati metodi contraccettivi. I metodi contraccettivi devono essere utilizzati dalla randomizzazione fino a 3 mesi dopo l’ultima somministrazione di trattamento in studio.
    E.4Principal exclusion criteria
    1. Exposure to another investigational drug within 3 months prior to the start of study treatment.
    2. Use of any pharmacologic treatment, other than corticosteroids, that might have an effect on muscle strength or function within 3 months prior to the start of study treatment (e.g., growth hormone). Vitamin D, calcium, and any other supplements will be allowed.
    3. Surgery that might affect muscle strength or function within 3 months before study entry or planned surgery at any time during the study.
    4. Presence of other clinically significant disease that in the Investigator’s opinion could adversely affect the safety of the patient, making it unlikely that the course of treatment or follow-up is completed, or could impair the assessment of study results.
    5. A diagnosis of other uncontrolled neurological diseases or presence of relevant somatic disorders not related to BMD that may interfere with the ability to perform the muscle function tests and/or to comply with the study protocol procedures.
    6. Platelet count, WBC count and hemoglobin at screening < Lower Limit of Normal (LLN). If laboratory screening results are < LLN, platelet count, WBC count and hemoglobin are to be repeated once, and if again < LLN become exclusionary.
    7. Symptomatic cardiomyopathy or heart failure (New York Heart Association Class III or IV) or left ventricular ejection fraction < 50% at screening or with heart transplant.
    8. Current liver disease or impairment, including but not limited to elevated total bilirubin (> 1.5 x ULN), unless secondary to Gilbert’s disease or pattern consistent with Gilbert's disease.
    9. Inadequate renal function, as defined by serum Cystatin C > 2 x the upper limit of normal (ULN). If the value is > 2 x ULN, serum Cystatin C will be repeated once, and if again > 2 x ULN becomes exclusionary.
    10. Positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus at screening.
    11. Baseline corrected QT interval, Fridericia’s correction (QTcF) > 450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome).
    12. Current psychiatric illness/social situations rendering the potential patient unable to understand and comply with the muscle function tests and/or with the study protocol procedures.
    13. Hypersensitivity to the components of study medication.
    14. Sorbitol intolerance or sorbitol malabsorption, or the hereditary form of fructose intolerance.
    15. Contraindications to muscle biopsy.
    16. Contraindications to MRI/MRS (e.g., claustrophobia, metal implants, or seizure disorder).
    17. Hypertriglyceridemia (¿ 1.5 x upper limit of normal [ULN])*
    * At screening, patients with hypertriglyceridemia can be enrolled if in stable treatment and with controlled levels of triglycerides (i.e. within normal range) for at least six months.
    1. Esposizione ad un altro farmaco sperimentale nei 3 mesi precedenti l’inizio del trattamento in studio.
    2. Utilizzo di qualsiasi trattamento farmacologico, diverso dai corticosteroidi, che possa avere un effetto sulla forza o sulla funzionalità muscolare nei 3 mesi prima dell’inizio del trattamento in studio (ad es. ormone della crescita). Sarà consentito l’uso di vitamina D, calcio e altri integratori.
    3. Intervento chirurgico che possa avere un impatto sulla forza o sulla funzionalità muscolare nei 3 mesi precedenti l’ingresso in studio o intervento chirurgico pianificato in qualsiasi momento durante lo studio.
    4. Presenza di altra patologia clinicamente significativa che, a giudizio dello Sperimentatore, potrebbe avere un impatto negativo sulla sicurezza del paziente, rendendo improbabile il completamento del ciclo di trattamento o del follow-up, o che potrebbe influenzare la valutazione dei risultati dello studio.
    5. Diagnosi di altre patologie neurologiche non controllate o presenza di disturbi somatici rilevanti non correlati alla BMD che possono interferire con la capacità di effettuare i test di funzionalità muscolare e/o di aderire alle procedure del protocollo di studio.
    6. Conta piastrinica, conta leucocitaria ed emoglobina allo screening al di sotto del limite inferiore di normalità (Lower Limit of Normal – LLN). Se i risultati di laboratorio allo screening sono < LLN, le valutazioni della conta piastrinica, della conta leucocitaria e dell’emoglobina devono essere ripetute una volta e, se ancora <LLN, costituiranno un criterio di esclusione.
    7. Cardiomiopatia sintomatica o scompenso cardiaco (Classe III o IV in base alla classificazione della New York Heart Association) o frazione di eiezione ventricolare sinistra < 50% allo screening o paziente con trapianto cardiaco.
    8. Attuale patologia o insufficienza epatica, compresa ma non limitata a elevata bilirubina totale (> 1.5 x Upper Limit of Normal – ULN), a meno che non secondaria a sindrome di Gilbert o con pattern coerente con sindrome di Gilbert.
    9. Funzionalità renale inadeguata, definita da cistatina C sierica > 2 x ULN. Se il valore è > 2 x ULN, la valutazione della cistatina C sierica sarà ripetuta una volta e, se ancora > x ULN, costituirà un criterio di esclusione.
    10. Test positivo per antigene di superficie dell’epatite B, anticorpi per epatite C o virus dell’immunodeficienza umana allo screening.
    11. Intervallo QT corretto con correzione di Fridericia (QTcF) al basale > 450 msec (come media di 3 letture consecutive effettuate a 5 minuti di intervallo una dall’altra) o anamnesi di fattori di rischio aggiuntivi per torsioni di punta (ad es. scompenso cardiaco, ipokaliemia, o anamnesi familiare di sindrome del QT lungo).
    12. Attuali patologia psichiatrica/situazioni sociali che rendono il potenziale paziente non in grado di comprendere e di effettuare correttamente i test di funzionalità muscolare e/o di aderire alle procedure del protocollo di studio.
    13. Ipersensibilità ai componenti del trattamento in studio.
    14. Intolleranza al sorbitolo o malassorbimento del sorbitolo, o forma ereditaria di intolleranza al fruttosio.
    15. Controindicazioni alla biopsia muscolare.
    16. Controindicazioni alla MRI/MRS (ad es. claustrofobia, impianti metallici, o disturbi convulsivi).
    17. Ipertrigliceridemia (> 1.5 x limite superiore di normalità (Upper Normal Limit – ULN)*
    * Allo screening, i pazienti con ipertrigliceridemia possono essere arruolati se in trattamento stabile e con livelli controllati di trigliceridi (ovvero, entro i limiti di normalità) da almeno sei mesi.
    E.5 End points
    E.5.1Primary end point(s)
    Mean change in mean Cross Sectional Area (CSA) comparing the histology of muscle biopsies.
    Variazione media nella CSA media confrontando l’istologia delle biopsie muscolari.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Before and after 12 months of treatment with givinostat versus placebo.
    Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo.
    E.5.2Secondary end point(s)
    Mean change in fat fraction of vastus lateralis comparing Magnetic Resonance Spectroscopy (MRS) ; Mean change in other histology parameters (e.g. MFA%, % of total fibrosis, regenerative fibers) comparing the histology biopsies; Mean change in Motor Function Measurement (MFM) ; Mean change in Time Function Tests (time to climb four standard steps, time to rise from floor and time to walk/run 10 m); Mean change in 6 Minute Walking Test (6MWT) ; Proportion of patients with < 10% worsening in 6MWT ; Proportion of patients who lose the ability to rise from floor ; Proportion of patients who lose ambulation ; Mean change in muscle strength evaluated by knee extension, elbow flexion as measured by Hand Held Myometry (HHM) ; Mean changes in quality of life (assessed by the 36-item Short Form survey [SF36]) ; Mean change in fat fraction of pelvic girdle and lower limb muscles comparing Magnetic Resonance Imaging (MRI); Mean CSA of pelvic girdle and lower limb muscles comparing MRI
    Variazione media nella frazione grassa del vasto laterale confrontando la MRS ; Variazione media di altri parametri istologici (ad es. % MFA, % di fibrosi totale, fibre rigenerative), confrontando l¿istologia delle biopsie ; Variazione media della misurazione della funzionalit¿ motoria (MFM); Variazione media dei test di funzionalit¿ cronometrati (tempo per salire quattro scalini standard, tempo per alzarsi dal pavimento e tempo per correre/camminare per 10 m) ; Variazione media del test del cammino in 6 minuti (6MWT) ; Proporzione di pazienti con peggioramento < 10% nel 6MWT; Proporzione di pazienti che perdono la capacit¿ di alzarsi dal pavimento ; Proporzione di pazienti che perdono la capacit¿ di deambulare ; Variazione media della forza muscolare valutata tramite estensione del ginocchio, flessione del gomito misurata con dispositivo portatile HHM; Variazioni medie nella qualit¿ della vita (valutata tramite questionario SF36) ; Variazione media nella frazione grassa dei muscoli del
    cingolo pelvico e degli arti inferiori confrontando l¿MRI; CSA media dei muscoli del cingolo pelvico e degli arti inferiori confrontando l¿MRI
    E.5.2.1Timepoint(s) of evaluation of this end point
    Before and after 12 months of treatment with givinostat versus placebo; Before and after 12 months of treatment with givinostat; Before and after 12 months of treatment with givinostat versus placebo. ; Before and after 12 months of treatment with givinostat versus placebo; Before and after 12 months of treatment with givinostat versus placebo; At the end of study.; Baseline through end of study; During the study; Before and after 12 months of treatment with givinostat versus placebo; Before and after 12 months of treatment with givinostat as compared to placebo; Before and after 12 months of treatment with givinostat versus placebo; Before and after 12 months of treatment with givinostat versus placebo
    Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Alla fine dello studio; Basale fino alla fine dello studio; Durante lo studio; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo; Prima e dopo 12 mesi di trattamento con givinostat rispetto a placebo
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Quality of life and daily activities
    Qualità della vita e attività della vita quotidiana
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA2
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 48
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state48
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 55
    F.4.2.2In the whole clinical trial 55
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the end of the study, the patient will return to your usual medical care.
    Al termine dello studio il paziente tornerà alle Sue cure mediche abituali.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation Parent Project Onlus
    G.4.3.4Network Country Italy
    G.4 Investigator Network to be involved in the Trial: 2
    G.4.1Name of Organisation Association Aide aux Familles d¿Enfants Handicap¿s Moteur (AFEHM)
    G.4.3.4Network Country France
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-07-18
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA